Seok Jin Kim1,2, Danbee Kang3,4,5, Im Ryung Kim5, Sang Eun Yoon2, Won Seog Kim1,2, Phyllis N Butow6, Eliseo Guallar7, Juhee Cho3,4,5,7. 1. Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea. 2. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea. 3. Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Science and Technology, School of Medicine, Sungkyunkwan University, Seoul, Korea. 4. Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University, Seoul, Korea. 5. Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea. 6. Centre for Medical Psychology and Evidence-based Decision-making, School of Psychology and Department of Medicine, University of Sydney, Sydney, NSW, Australia. 7. Departments of Epidemiology and Medicine and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Abstract
OBJECTIVE: This study aimed to evaluate fear of cancer recurrence (FCR) among lymphoma patients who completed treatment and its impact on survival and quality of life (QOL). METHODS: In this prospective cohort study, 467 lymphoma patients were included who completed treatment with curative intent between February 2012 and March 2017. FCR was measured using a question from the Korean version of the QOL in Cancer Survivors Questionnaire. QOL and general health and functioning were measured using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30. Participants were actively followed up for all-cause and disease-specific mortality. RESULTS: In total, 16.3% of the patients had severe FCR. The adjusted hazard ratio (HR) for all-cause mortality comparing participants with and without severe FCR was 2.52 (95% CI = 1.15-5.54), and the association was stronger in indolent non-Hodgkin lymphoma (NHL) (HR = 6.77; 95% CI = 1.04-43.92). Participants with severe FCR were also at higher risk of lymphoma-specific mortality (HR = 2.62; 95% CI = 1.13-6.05) than patients without severe FCR. Patients with severe FCR had significantly worse general health status (64.3 vs 71.0, P = .03) and physical (82.4 vs 76.7, P < .01), emotional (68.5 vs 84.8, P < .001), and social functioning (67.8 vs 84.2, P < .001) than patients without severe FCR. CONCLUSIONS: A substantial number of participants with lymphoma experience FCR after treatment completion, even in the case of indolent lymphomas. Given the negative impact of severe FCR on survival and general health and functional status, active monitoring and appropriate management of FCR should be considered in clinical settings.
OBJECTIVE: This study aimed to evaluate fear of cancer recurrence (FCR) among lymphomapatients who completed treatment and its impact on survival and quality of life (QOL). METHODS: In this prospective cohort study, 467 lymphomapatients were included who completed treatment with curative intent between February 2012 and March 2017. FCR was measured using a question from the Korean version of the QOL in Cancer Survivors Questionnaire. QOL and general health and functioning were measured using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30. Participants were actively followed up for all-cause and disease-specific mortality. RESULTS: In total, 16.3% of the patients had severe FCR. The adjusted hazard ratio (HR) for all-cause mortality comparing participants with and without severe FCR was 2.52 (95% CI = 1.15-5.54), and the association was stronger in indolent non-Hodgkin lymphoma (NHL) (HR = 6.77; 95% CI = 1.04-43.92). Participants with severe FCR were also at higher risk of lymphoma-specific mortality (HR = 2.62; 95% CI = 1.13-6.05) than patients without severe FCR. Patients with severe FCR had significantly worse general health status (64.3 vs 71.0, P = .03) and physical (82.4 vs 76.7, P < .01), emotional (68.5 vs 84.8, P < .001), and social functioning (67.8 vs 84.2, P < .001) than patients without severe FCR. CONCLUSIONS: A substantial number of participants with lymphoma experience FCR after treatment completion, even in the case of indolent lymphomas. Given the negative impact of severe FCR on survival and general health and functional status, active monitoring and appropriate management of FCR should be considered in clinical settings.
Authors: Mohamad S Alabdaljabar; Ibrahim N Muhsen; Jennifer M Knight; Karen L Syrjala; Shahrukh K Hashmi Journal: Blood Rev Date: 2020-12-01 Impact factor: 8.250
Authors: Danbee Kang; Ka Ryeong Bae; Jihyun Lim; Nayeon Kim; Sungkeun Shim; Sun Seog Kweon; Hwa Jeong Seo; Juhee Cho Journal: Support Care Cancer Date: 2022-02-16 Impact factor: 3.603
Authors: Esther N Pijnappel; Willemieke P M Dijksterhuis; Mirjam A G Sprangers; Simone Augustinus; Judith de Vos-Geelen; Ignace H J T de Hingh; Izaak Q Molenaar; Olivier R Busch; Marc G Besselink; Johanna W Wilmink; Hanneke W M van Laarhoven Journal: Support Care Cancer Date: 2022-02-15 Impact factor: 3.359